Ono Pharmaceutical sales and marketing update

Ono launched Opdivo nivolumab in Japan to treat unresectable melanoma. The Japanese National Health Insurance (NHI) list price is Y728,849 ($6,996.95) for a 100 mg vial and Y150,200 ($1,441.92) for a 20 mg vial. The recommended dose for the human IgG4 mAb against programmed cell death 1 ( PDCD1; PD-1; CD279) is 2 mg/kg every three weeks. ...